Hospira Epirubicin Hydrochloride Injection 50mg/25mL Hospira

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

epirubicin hydrochloride, Quantity: 2 mg/mL

Disponibbli minn:

Hospira Australia Pty Ltd

INN (Isem Internazzjonali):

epirubicin hydrochloride

Għamla farmaċewtika:

Injection, solution

Kompożizzjoni:

Excipient Ingredients: sodium chloride; water for injections

Rotta amministrattiva:

Intravenous Infusion

Unitajiet fil-pakkett:

1 Vial per pack

Klassi:

Medicine Listed (Export Only)

Tip ta 'preskrizzjoni:

(S1) This Schedule is intentionally blank

Indikazzjonijiet terapewtiċi:

1. Relief of subjective and objective symptoms in the following diseases: Acute leukaemia, malignant lymphoma, breast cancer, ovarian cancer, stomach cancer, liver cancer, urothelial cancer (bladder cancer, renal pelvic/ureteral cancer) 2. Treatment of the following malignant cancer in conjunction with other anti-malignant cancer drugs: Breast cancer (pre- and post-operative chemotherapy in operable cases)

Sommarju tal-prodott:

Visual Identification: Epirubicin Hydrochloride Injeciton is a clear red solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2013-05-08